Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Net Income (2018 - 2025)

Historic Net Income for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to -$7.4 million.

  • Cue Biopharma's Net Income rose 1297.21% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.3 million, marking a year-over-year increase of 1421.73%. This contributed to the annual value of -$39.9 million for FY2024, which is 1941.88% up from last year.
  • As of Q3 2025, Cue Biopharma's Net Income stood at -$7.4 million, which was up 1297.21% from -$8.4 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Net Income registered a high of -$7.4 million during Q3 2025, and its lowest value of -$14.3 million during Q1 2022.
  • In the last 5 years, Cue Biopharma's Net Income had a median value of -$12.1 million in 2024 and averaged -$11.2 million.
  • In the last 5 years, Cue Biopharma's Net Income tumbled by 8042.44% in 2022 and then soared by 2772.49% in 2024.
  • Cue Biopharma's Net Income (Quarter) stood at -$7.9 million in 2021, then plummeted by 80.42% to -$14.2 million in 2022, then rose by 9.18% to -$12.9 million in 2023, then rose by 27.72% to -$9.3 million in 2024, then grew by 21.09% to -$7.4 million in 2025.
  • Its last three reported values are -$7.4 million in Q3 2025, -$8.4 million for Q2 2025, and -$12.1 million during Q1 2025.